8-K: Oragenics Faces Delisting Threat After Failing to Meet NYSE American Listing Standards

Oragenics, Inc. has received a notice from the NYSE American for non-compliance with continued listing standards due to insufficient stockholders' equity.

Summary

• Oragenics, Inc. received a notification from the NYSE American on April 18, 2024, stating that the company is not in compliance with continued listing standards.
• The non-compliance is due to the company's stockholders' equity being below the required thresholds of $4 million and $6 million, as outlined in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide.
• Oragenics reported stockholders' equity of $3.2 million as of December 31, 2023, and has experienced losses from continuing operations and/or net losses in its five most recent fiscal years.
• The company must submit a plan of compliance by May 18, 2024, detailing how it intends to regain compliance by October 18, 2025.
• If the plan is not submitted, not accepted, or if the company fails to meet the standards by the deadline, it will be subject to delisting procedures.
• The company's stock will continue to trade on the NYSE American under the symbol OGEN, but with an added designation of '.BC' to indicate its non-compliance status.
• The notice does not immediately impact the company's business operations or SEC reporting requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting threat and the company's poor financial position. While the company is working on a plan, there is no guarantee of success, and the potential consequences are severe.

Positives

• The notice has no immediate impact on the listing of the company's shares, which will continue to trade on the NYSE American during the plan period.
• The company is committed to undertaking transactions to achieve compliance with the NYSE American requirements.

Negatives

• The company's stockholders' equity is below the required thresholds for continued listing.
• The company has reported losses from continuing operations and/or net losses in its five most recent fiscal years.
• Failure to submit or have an accepted plan could lead to delisting.
• Delisting could negatively impact the company's stock liquidity, market price, and ability to raise capital.

Risks

• There is no assurance that the company will be able to achieve compliance with the NYSE American's continued listing standards within the required timeframe.
• Delisting could reduce the liquidity and market price of the company's common stock.
• Delisting could reduce the number of investors willing to hold or acquire the common stock, impacting the company's ability to raise equity financing.
• Delisting could limit the company's ability to use a registration statement to offer and sell freely tradable securities.
• Delisting could impair the company's ability to provide equity incentives to its employees.

Future Outlook

The company is committed to undertaking transactions to achieve compliance with the NYSE American's requirements, but there is no assurance that it will be able to do so within the required timeframe.

Management Comments

• The company is committed to undertaking a transaction or transactions in the future to achieve compliance with the NYSE American's requirements.
• The company has begun to prepare its plan for submission to the NYSE American by the May 18, 2024 deadline.

Industry Context

This announcement highlights the challenges faced by development-stage biotechnology companies in maintaining listing compliance, particularly those with ongoing losses and limited revenue. It is not uncommon for companies in this sector to face delisting risks if they cannot meet financial requirements.

Comparison to Industry Standards

• Many development-stage biotech companies face similar challenges in maintaining listing compliance due to high R&D costs and lack of revenue.
• Companies like Athersys and Ocugen have also faced delisting warnings in the past due to low stock prices and market capitalization, highlighting the volatility and risk in this sector.
• The specific equity requirements of $4 million and $6 million are standard for the NYSE American, and failure to meet these is a common reason for non-compliance notices.
• Oragenics' situation is not unique, but the company's ability to execute a plan to regain compliance will be critical for its future.

Stakeholder Impact

• Shareholders face the risk of delisting, which could negatively impact the value of their investment.
• Employees may be concerned about the company's future and the potential impact on their equity incentives.
• Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

• The company must submit a plan of compliance to the NYSE American by May 18, 2024.
• The company must regain compliance with the NYSE American's continued listing standards by October 18, 2025.
• The company will be subject to continued periodic review by the NYSE American staff during the plan period.

Key Dates

Keywords

delisting, NYSE American, compliance, stockholders equity, financial losses, Oragenics, OGEN, biotechnology